Myasthenia gravis
RecruitingStudy on the Safety and Effectiveness of NMD670 for Adults with Myasthenia Gravis
- Disease:Myasthenia gravis
- Substances:Nmd670
Belgium- Participants:18–64 years · 65+ years
- Substances:Nmd670
- Sponsor:NMD Pharma A/S
Rare diseases
Investigational molecules
Locations

Palle Juul-Jensens Boulevard 82, 8200 Aarhus, Denmark
Research activity is centred on neuromuscular disease, with studies in Charcot-Marie-Tooth disease, myasthenia gravis, and spinal muscular atrophy. The portfolio reflects a focus on conditions that affect muscle strength, mobility, and neuromuscular function.
These programmes indicate sustained interest in disorders with impaired peripheral nerve or neuromuscular transmission, especially in adult patient populations.
NMD Pharma A/S runs clinical trials in conditions such as Myasthenia gravis, Spinal muscular atrophy, Hereditary motor and sensory neuropathy, among others.
Clinical trials run by this sponsor – those enrolling participants first.
Belgium
Belgium
BelgiumIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.